Precision Nutrition Versus Standard Dietary Care: Continuous Glucose Monitoring as a Tool for Guided Nutrition Care in Type 2 Diabetes - The PRECISE-DIET Trial. -A Pilot Study
1 other identifier
interventional
20
1 country
1
Brief Summary
The primary aim of this pilot study is to assess the feasibility of a 12-week dietary intervention combined with the use of CGM in adults with T2D. The results of the pilot study will provide insights into recruitment, design, and the effectiveness of the intervention for the future long-term (12-month) PRECISE-DIET STUDY
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable type-2-diabetes
Started Nov 2025
Shorter than P25 for not_applicable type-2-diabetes
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 9, 2025
CompletedFirst Posted
Study publicly available on registry
February 18, 2025
CompletedStudy Start
First participant enrolled
November 18, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2026
February 10, 2026
November 1, 2025
10 months
January 9, 2025
February 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fidelity testing
Participants will be invited to a workshop to evaluate the intervention and its components. Procedures from fidelity testing will be applied in the evaluation. These specific topics will be evaluated: * Study design o Is the design appropriate? E.g., number of visits, CGM use, dietetic feedback? * Sampling strategy o E.g., how many participated, recruitment methods, sample diversity? * Treatment receipt * "What is learned?" * Is the intervention relevant to and accepted by the participants? * Treatment enactment * What is actually used and done? * Do participants' "behavioural skills" improve?
12 weeks after baseline
Secondary Outcomes (15)
HbA1c (mmol/mol)
Measured at baseline and after 12 weeks
Time in range (TIR)
Measured at baseline and after 12 weeks
Time above range (TAR)
Measured at baseline and after 12 weeks
Time below range (TBR)
Measured at baseline and after 12 weeks
Coefficient of variation (CV)
Measured at baseline and after 12 weeks
- +10 more secondary outcomes
Other Outcomes (3)
Changes in glucose lowering drugs
Measured at baseline and after 12 weeks
Personality trait assesment
Baseline
Physical activity
Measured at baseline and after 12 weeks
Study Arms (1)
Precise diet intervention
EXPERIMENTALThe precise diet intervention for 12 weeks (n=20).
Interventions
The intervention includes training and education in CGM use and reduction in overall carbohydrate intake guided by individualized flexible nutrition recommendations, with adjustments made according to postprandial blood glucose responses. Staff will guide participants in the daily carbohydrate intake with personalized adjustments to accommodate individual needs by the individuals. The primary goal is to minimize the participant's time spent above 10 mmol/l
Eligibility Criteria
You may qualify if:
- T2D
- Diabetes duration of ≥12 months
- ≥18 years of age
- HbA1c ≥58 mmol/mol
- Attending the SDCC outpatient clinic
- Provided voluntary signed informed consent.
You may not qualify if:
- Inability to understand the patient information.
- Complications which do not permit to lowering HbA1c to \<58 mmol/mol.
- Treatment with insulin.
- Systematic use of corticosteroids.
- Using or requiring a specialized diet (e.g., kidney diet).
- Circumstances that affect HbA1c (e.g., liver disease and anaemia).
- Known or suspected drug or alcohol abuse (judged by the investigator).
- Pregnancy or breastfeeding or plans of pregnancy within the study period.
- Participation in other clinical trials.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Steno Diabetes Center Copenhagen
Herlev, 2730, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bettina Ewers, PhD
Steno Diabetes Center Copenhagen
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Nutrition and PhD
Study Record Dates
First Submitted
January 9, 2025
First Posted
February 18, 2025
Study Start
November 18, 2025
Primary Completion (Estimated)
August 31, 2026
Study Completion (Estimated)
August 31, 2026
Last Updated
February 10, 2026
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share